A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Apr 2016

At a glance

  • Drugs Recanaclotide (Primary)
  • Indications Diabetic gastroparesis
  • Focus Therapeutic Use
  • Sponsors Ironwood Pharmaceuticals
  • Most Recent Events

    • 05 Apr 2016 According to Ironwood Pharmaceuticals media release, the company has announced top-line data, and intends to discontinue development of IW-9179 for gastroparesis.
    • 06 Jan 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 09 Dec 2014 Results are expected in the first half of 2016, according to an Ironwood Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top